Phase I study of orally administered 14Carbon-isotope labelled-vistusertib (AZD2014), a dual TORC1/2 kinase inhibitor, to assess the absorption, metabolism, excretion, and pharmacokinetics in patients with advanced solid malignancies
MacDonald, Alexander, Scarfe, Graeme, Magirr, Dominic, Sarvotham, Tinnu, Charlton, Julie, Brugger, Wolfram, Dean, EmmaМова:
english
Журнал:
Cancer Chemotherapy and Pharmacology
DOI:
10.1007/s00280-019-03781-x
Date:
February, 2019
Файл:
PDF, 834 KB
english, 2019
File converter
Більше результатів пошуку
More benefits 
